Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the breast
• * Recurrent or metastatic (stage IV) disease
• * Incurable disease
• Measurable or evaluable disease
• Stable brain metastases allowed
• Hormone receptor status:
• * Not specified
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Sex
• Female
• Menopausal status
• Not specified
• Performance status
• ECOG 0-1
• Life expectancy
• More than 3 months
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 8.0 g/dL
• Hepatic
• Bilirubin normal
• AST/ALT ≤ 2.5 times upper limit of normal
• Renal
• Creatinine normal OR
• Creatinine clearance ≥ 60 mL/min
• No clinically significant proteinuria
• No impaired renal function
• Cardiovascular
• No symptomatic congestive heart failure
• No unstable angina
• No cardiac arrhythmia
• No inadequately controlled hypertension
• Gastrointestinal
• No disorder that would alter gastrointestinal motility or absorption
• No dysphagia
• Able to swallow tablets or capsules
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No hypersensitivity to celecoxib
• * No prior urticaria, asthma, or other allergic-type reaction after taking aspirin or other nonsteroidal anti-inflammatory drugs
• No allergy to sulfa
• No other concurrent uncontrolled illness
• No psychiatric illness or social situation that would preclude study compliance
• No ongoing or active infection
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• At least 3 weeks since prior trastuzumab (Herceptin®) and recovered
• No concurrent hematopoietic growth factors
• Chemotherapy
• At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• Prior adjuvant or neoadjuvant chemotherapy allowed
• Prior chemotherapy for recurrent or metastatic disease allowed
• No prior vinorelbine
• Endocrine therapy
• At least 2 weeks since prior hormonal therapy
• Prior adjuvant or neoadjuvant hormonal therapy allowed
• Prior hormonal therapy for recurrent or metastatic disease allowed
• Radiotherapy
• At least 4 weeks since prior radiotherapy for metastatic disease
• Prior adjuvant radiotherapy allowed
• Surgery
• Not specified
• Other
• At least 3 weeks since prior investigational anticancer agents and recovered
• At least 1 week since prior cyclooxygenase-2 (COX-2) inhibitors, except celecoxib
• No concurrent administration of any of the following drugs:
• * Lithium
• * Fluconazole
• * Aluminum antacids
• * Magnesium antacids
• Concurrent H\_2 blocking agents or proton pump inhibitors allowed for the treatment of dyspepsia or gastroesophageal reflux disease
• Concurrent bisphosphonates allowed